With 1.04 million shares changed hands, the volume of the stock remained heavier than its average volume of 0.5 million shares. During the session, the Biotechnology company that operates in wider Healthcare sector, reached to the highest price of $1.1500 whereas the lowest price it dropped to was $1.0700. The 52-week range on ATAI shows that it touched its highest point at $3.65 and its lowest point at $1.05 during that stretch. It currently has a 1-year price target of $12.35. Beta for the stock currently stands at 0.76.
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of ATAI was down-trending over the past week, with a drop of -5.13%, but this was down by -13.95% over a month. Three-month performance dropped to -31.90% while six-month performance fell -40.96%. The stock lost -61.32% in the past year, while it has lost -58.27% so far this year. A look at the trailing 12-month EPS for ATAI yields -0.42 with Next year EPS estimates of -0.81. For the next quarter, that number is -0.16. This implies an EPS growth rate of 58.27% for this year and -97.89% for next year.
Float and Shares Shorts:
At present, 165.94 million ATAI shares are outstanding with a float of 114.10 million shares on hand for trading. On Oct 30, 2023, short shares totaled 5.63 million, which was 3.39% higher than short shares on Sep 28, 2023. In addition to Mr. Christian Angermayer as the firm’s Founder & Chairman of the Supervisory Board, Mr. Florian Brand serves as its Co-founder & CEO.
Institutional Ownership:
Through their ownership of 30.33% of ATAI’s outstanding shares, institutional investors have minority control over the company. Other institutions hold 5.25% of ATAI, in contrast to 3.81% held by mutual funds. Shares owned by individuals account for 21.54%. As the largest shareholder in ATAI with 0.95% of the stake, Morgan Stanley Investment Managem holds 1,582,134 shares worth 1,582,134. A second-largest stockholder of ATAI, BlackRock Fund Advisors, holds 1,421,354 shares, controlling over 0.86% of the firm’s shares. BMO Asset Management Corp. is the third largest shareholder in ATAI, holding 970,455 shares or 0.59% stake. With a 0.49% stake in ATAI, the iShares Biotechnology ETF is the largest stakeholder. A total of 812,660 shares are owned by the mutual fund manager. The SPDR S&P Kensho New Economies Com, which owns about 0.41% of ATAI stock, is the second-largest Mutual Fund holder. It holds 679,782 shares valued at 0.84 million. Morgan Stanley Instl. Fund Tr. – holds 0.34% of the stake in ATAI, owning 570,330 shares worth 0.7 million.
Analysts Ratings:
Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for ATAI since 0 analysts follow the stock currently. In the same way, a target price assigned to a stock can also reveal much about its potential. With ATAI analysts setting a high price target of $21.00 and a low target of $5.10, the average target price over the next 12 months is $12.35. Based on these targets, ATAI could surge 1791.89% to reach the target high and rise by 359.46% to reach the target low. Reaching the average price target will result in a growth of 1012.61% from current levels.
